Covered recipient · General Payments record
JAMES QUINTEN DEL ROSSO
Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$252,052.76
151 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $117,150.00 | 43 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,260.73 | 31 |
| Consulting Fee | $63,257.50 | 20 |
| Travel and Lodging | $3,570.22 | 14 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,800.00 | 2 |
| Food and Beverage | $1,974.36 | 40 |
| Education | $39.95 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | $67,187.25 | 26 |
| VYNE Pharmaceuticals Inc. | $34,092.95 | 19 |
| Almirall LLC | $21,793.79 | 11 |
| LEO Pharma Inc. | $15,838.61 | 8 |
| Amgen Inc. | $15,688.93 | 21 |
| Galderma Laboratories, L.P. | $15,344.69 | 9 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $15,344.26 | 6 |
| GENZYME CORPORATION | $13,072.03 | 10 |
| MAYNE PHARMA INC. | $11,262.64 | 6 |
| DERMIRA, INC. | $9,924.20 | 7 |
| UCB, Inc. | $9,246.59 | 9 |
| PFIZER INC. | $8,775.00 | 3 |
| EPI Health, LLC | $7,600.00 | 6 |
| Regeneron Healthcare Solutions, Inc. | $4,362.89 | 5 |
| Incyte Corporation | $2,400.00 | 1 |
| Celgene Corporation | $52.89 | 1 |
| SANOFI-AVENTIS U.S. LLC | $30.07 | 1 |
| Lilly USA, LLC | $21.13 | 1 |
| AbbVie Inc. | $14.84 | 1 |
Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES QUINTEN DEL ROSSO
NPI 1083636369 · CMS profile ID 3970
Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery
LAS VEGAS, NV
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1083636369?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES QUINTEN DEL ROSSO, NPI 1083636369, CMS profile ID 3970. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083636369?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JAMES QUINTEN DEL ROSSO, NPI 1083636369, CMS profile ID 3970. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083636369?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JAMES QUINTEN DEL ROSSO, NPI 1083636369, CMS profile ID 3970, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1083636369?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
151 matching records · $252,052.76 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 151.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $623.00 | 08/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741396805 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,600.00 | 08/13/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236573 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,600.00 | 08/13/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236605 | CMS |
| Almirall LLC | $74.27 | 08/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728053163 | CMS |
| Almirall LLC | $5,850.00 | 08/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728053667 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $2,100.00 | 08/04/2020 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737459565 | CMS |
| Galderma Laboratories, L.P. | $2,700.00 | 07/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726840039 | CMS |
| UCB, Inc. | $39.95 | 07/24/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746107049 | CMS |
| EPI Health, LLC | $1,200.00 | 07/23/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753163425 | CMS |
| LEO Pharma Inc. | $630.00 | 07/17/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746671797 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $2,860.00 | 07/15/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737459563 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,930.50 | 07/14/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724419251 | CMS |
| Galderma Laboratories, L.P. | $1,200.00 | 07/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726840037 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,600.00 | 06/25/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236571 | CMS |
| VYNE Pharmaceuticals Inc. | $1,800.00 | 06/25/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194673 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,600.00 | 06/23/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236569 | CMS |
| VYNE Pharmaceuticals Inc. | $1,800.00 | 06/18/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194667 | CMS |
| MAYNE PHARMA INC. | $3,750.00 | 06/12/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719708589 | CMS |
| Galderma Laboratories, L.P. | $1,200.00 | 06/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726840033 | CMS |
| LEO Pharma Inc. | $1,500.00 | 06/03/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746671793 | CMS |
| PFIZER INC. | $975.00 | 06/01/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743226567 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,600.00 | 05/20/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236567 | CMS |
| VYNE Pharmaceuticals Inc. | $3,300.00 | 05/20/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194679 | CMS |
| MAYNE PHARMA INC. | $3,750.00 | 05/15/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719712565 | CMS |
| EPI Health, LLC | $2,400.00 | 05/14/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753163423 | CMS |
| Amgen Inc. | $1,246.00 | 05/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741396801 | CMS |
| MAYNE PHARMA INC. | $1,875.00 | 05/08/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719704853 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $5,005.00 | 05/07/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737459561 | CMS |
| VYNE Pharmaceuticals Inc. | $1,800.00 | 05/06/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194669 | CMS |
| Almirall LLC | $1,500.00 | 05/04/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728044185 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,600.00 | 04/30/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236565 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,600.00 | 04/30/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236603 | CMS |
| Almirall LLC | $1,500.00 | 04/29/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728044203 | CMS |
| VYNE Pharmaceuticals Inc. | $1,800.00 | 04/29/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194665 | CMS |
| LEO Pharma Inc. | $1,500.00 | 04/22/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746671789 | CMS |
| VYNE Pharmaceuticals Inc. | $1,800.00 | 04/22/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194661 | CMS |
| VYNE Pharmaceuticals Inc. | $1,800.00 | 04/15/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194663 | CMS |
| Almirall LLC | $1,500.00 | 04/09/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728042365 | CMS |
| MAYNE PHARMA INC. | $1,250.00 | 04/08/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719701795 | CMS |
| UCB, Inc. | $2,240.00 | 03/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746052071 | CMS |
| UCB, Inc. | $840.00 | 03/31/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746097741 | CMS |
| MAYNE PHARMA INC. | $625.00 | 03/27/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719708953 | CMS |
| Sun Pharmaceutical Industries Inc. | $249.96 | 03/26/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236587 | CMS |
| Regeneron Healthcare Solutions, Inc. | $526.50 | 03/17/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724419249 | CMS |
| Sun Pharmaceutical Industries Inc. | $6,000.00 | 03/12/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236559 | CMS |
| Sun Pharmaceutical Industries Inc. | $108.35 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236561 | CMS |
| Sun Pharmaceutical Industries Inc. | $862.77 | 03/12/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236589 | CMS |
| Sun Pharmaceutical Industries Inc. | $186.55 | 03/12/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728236591 | CMS |
| VYNE Pharmaceuticals Inc. | $23.33 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194689 | CMS |
| VYNE Pharmaceuticals Inc. | $46.17 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753194693 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $269,623.80 | 53 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $206,570.35 | 118 |
| PY2023 | Principal investigator | $155,960.99 | 42 |
| PY2022 | Principal investigator | $246,463.82 | 46 |
| PY2021 | Recipient | $5,000.00 | 1 |
| PY2021 | Principal investigator | $235,558.16 | 42 |
| PY2020 | Principal investigator | $373,027.22 | 40 |
| PY2019 | Principal investigator | $293,390.83 | 67 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
53 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $3,918.00 | 12/19/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540968 |
| Principal investigator 1 | Incyte Corporation | $1,075.00 | 12/19/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540989 |
| Principal investigator 1 | Incyte Corporation | $1,586.00 | 12/19/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540992 |
| Principal investigator 1 | Incyte Corporation | $1,419.00 | 12/19/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540996 |
| Principal investigator 1 | Incyte Corporation | $2,168.00 | 12/19/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240541001 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,233.20 | 12/18/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH LLC | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289930 |
| Principal investigator 1 | Incyte Corporation | $1,890.00 | 12/11/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540971 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $34,988.20 | 12/11/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH LLC | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289566 |
| Principal investigator 1 | Incyte Corporation | $889.60 | 12/05/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540981 |
| Principal investigator 1 | Incyte Corporation | $5,538.00 | 12/04/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540963 |
| Principal investigator 1 | Incyte Corporation | $5,468.50 | 11/26/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540955 |
| Principal investigator 1 | Incyte Corporation | $10,296.60 | 11/26/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540960 |
| Principal investigator 1 | Incyte Corporation | $1,364.40 | 11/21/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540976 |
| Principal investigator 1 | Incyte Corporation | $2,234.00 | 11/14/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540948 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $41,641.60 | 11/03/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH LLC | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287877 |
| Principal investigator 1 | Incyte Corporation | $1,890.00 | 10/28/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540932 |
| Principal investigator 1 | Eli Lilly and Company | $10,010.00 | 10/23/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187886022 |
| Principal investigator 1 | Incyte Corporation | $3,209.00 | 10/23/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540940 |
| Principal investigator 1 | Incyte Corporation | $647.00 | 10/22/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540974 |
| Principal investigator 1 | Incyte Corporation | $1,586.00 | 10/22/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540985 |
| Principal investigator 1 | Incyte Corporation | $2,168.00 | 10/22/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240541004 |
| Principal investigator 1 | Incyte Corporation | $2,168.00 | 10/22/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240541008 |
| Principal investigator 1 | Incyte Corporation | $73.00 | 10/22/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240541013 |
| Principal investigator 1 | Incyte Corporation | $1,890.00 | 10/16/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540944 |
| Principal investigator 1 | Incyte Corporation | $2,028.00 | 10/09/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540936 |
| Principal investigator 1 | Incyte Corporation | $8,102.00 | 09/23/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540927 |
| Principal investigator 1 | Incyte Corporation | $2,636.00 | 09/11/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540923 |
| Principal investigator 1 | Incyte Corporation | $3,209.00 | 09/04/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540929 |
| Principal investigator 1 | Incyte Corporation | $5,325.00 | 08/26/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540918 |
| Principal investigator 1 | Incyte Corporation | $3,303.00 | 08/21/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540911 |
| Principal investigator 1 | Incyte Corporation | $7,117.00 | 08/07/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540915 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,200.00 | 08/01/2025 | Non-covered Recipient Entity Jdr Dermatology Research | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235996489 |
| Principal investigator 1 | Incyte Corporation | $3,071.00 | 07/17/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540906 |
| Principal investigator 1 | Incyte Corporation | $6,074.00 | 07/10/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540902 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,400.00 | 07/02/2025 | Non-covered Recipient Entity Jdr Dermatology Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226104708 |
| Principal investigator 1 | Incyte Corporation | $7,526.00 | 06/24/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540898 |
| Principal investigator 1 | Incyte Corporation | $1,279.00 | 06/19/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540892 |
| Principal investigator 1 | Incyte Corporation | $5,134.00 | 06/12/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540888 |
| Principal investigator 1 | Incyte Corporation | $1,950.00 | 05/27/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540872 |
| Principal investigator 1 | Incyte Corporation | $975.00 | 05/15/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540876 |
| Principal investigator 1 | Incyte Corporation | $304.00 | 05/08/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540884 |
| Principal investigator 1 | Incyte Corporation | $2,573.00 | 05/02/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540880 |
| Principal investigator 1 | Incyte Corporation | $1,890.00 | 04/17/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540863 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 04/17/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH LLC | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278198 |
| Principal investigator 1 | Incyte Corporation | $3,996.00 | 04/10/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540868 |
| Principal investigator 1 | Incyte Corporation | $4,983.00 | 04/03/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540858 |
| Principal investigator 1 | Eli Lilly and Company | $1,084.80 | 03/25/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187883002 |
| Principal investigator 1 | Incyte Corporation | $14,662.50 | 03/20/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540846 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 03/01/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540851 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 03/01/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540854 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,459.00 | 02/12/2025 | Non-covered Recipient Entity Jdr Dermatology Research | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235996487 |
| Principal investigator 1 | Incyte Corporation | $1,494.90 | 01/17/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240541022 |
| Principal investigator 1 | Incyte Corporation | $4,279.50 | 01/03/2025 | Non-covered Recipient Entity JDR DERMATOLOGY RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240541017 |